Masimo Corporation Announces New Study Investigates the Impact of ORi-Guided Oxygen Titration on Hyperoxemia-Mediated Morbidity During One-Lung Ventilation
June 14, 2021 at 02:00 am EDT
Share
Masimo Corporation announced the findings of a study published in the Turkish Journal of Medical Sciencesin which Dr. Ayten Saracoglu and colleagues at the Marmara University Pendik Training and Research Hospital in Istanbul evaluated the ability of ORi to guide oxygenation by measuring its impact on hyperoxemia-mediated morbidity during one-lung ventilation (OLV) conducted as part of thoracic surgery.1 They concluded that ORi-guided oxygen titration “may reduce hospital stay and increase patient safety. ORi, available outside the U.S. since 2014, is a noninvasive and continuous parameter intended to provide additional insight into a patient’s oxygen status under supplemental oxygen. Enabled by the multi-wavelength rainbow® Pulse CO-Oximetry platform, ORi is provided alongside oxygen saturation (SpO2) measured by clinically proven Masimo SET® pulse oximetry. Noting that during OLV, a common technique for facilitating a wide variety of pulmonary procedures, 100% fraction of inspired oxygen (FiO2) supplemental oxygen administration is commonly used, which exposes patients to the possibility of hyperoxia-induced lung injury, the researchers sought to determine whether ORi could “protect patient from the harmful effects of hyperoxemia with a noninvasive probe during OLV.” The researchers found that ORi monitoring was associated with significantly shorter duration of OLV with FiO2 > 60%, with significantly lower mean FiO2 values during OLV, and with lower recorded PaO2 values. They also found that the duration of FiO2 > 80% during OLV was strongly correlated with longer hospital stays (p < 0.001). The observation that mean FiO2 values were found to be significantly lower in the ORi groups (3 and 4), compared to the groups without ORi (1 and 2), led the researchers to hypothesize that “the risk of hyperoxia will be lower in patients undergoing ORi monitor[ing].” The researchers noted, “ORi cannot replace arterial blood gas analysis; however, it is useful to assess oxygenation. In groups without ORi monitors, the FiO2 was significantly higher than 80%. Moreover, in study, it was revealed that these patients had a longer hospital stay.
Masimo Corporation is a global technology company that develops and produces a range of monitoring technologies, including measurements, sensors, patient monitors, and automation and connectivity solutions. The Company's segments include Healthcare and Non-healthcare. Its Healthcare segment develops, manufactures and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. The Company's measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry and advanced rainbow Pulse CO-Oximetry parameters. The Company's Non-healthcare business develops, manufactures, markets, sells home sound integration technologies and accessories, along with licensing complete high performance in-vehicle audio systems under consumer brands, such as Bowers & Wilkins, Denon, Marantz, HEOS, Classe, Polk Audio, Boston Acoustics, and Definitive Technology.
Masimo Corporation Announces New Study Investigates the Impact of ORi-Guided Oxygen Titration on Hyperoxemia-Mediated Morbidity During One-Lung Ventilation